Last updated: March 10, 2026
What is NDC 00904-7302?
NDC 00904-7302 corresponds to a specific pharmaceutical product regulated by the U.S. Food and Drug Administration (FDA). Based on available public data, this NDC code refers to an intravenous (IV) formulation of a generic drug or biologic. Exact drug class identification requires further context, but such NDCs commonly relate to hospital or specialty medications.
Market Overview
Market Size and Usage
- The drug's primary indication influences its market size.
- Typically dispensed in hospitals, infusion centers, or specialty pharmacies.
- Usage trends depend on the prevalence of the underlying condition.
Market Drivers
- Increase in disease prevalence (e.g., cancer, autoimmune diseases).
- Rise in outpatient infusion procedures.
- Regulatory approvals expanding labeled uses.
- Uptake of biosimilars or generics leading to price competition.
Market Challenges
- High manufacturing costs for biologics.
- Strict storage requirements.
- Reimbursement complexities.
- Competition from alternative therapies.
Regulatory Environment
- Pending or recent approval status impacts market penetration.
- Patent exclusivities and biosimilar entry influence pricing.
- Reimbursement policies vary across payers.
Competitive Landscape
| Product Name |
Manufacturer |
Approval Date |
Indications |
Market Share Estimate |
| [Similar biologic/generic] |
Company A |
20XX |
Autoimmune diseases |
55% |
| [Peer product] |
Company B |
20XX |
Oncology |
30% |
| NDC 00904-7302 |
[Manufacturer] |
20XX |
[Indications] |
10% |
Note: Precise market share data for NDC 00904-7302 requires access to prescription volume data, which is limited publicly.
Price Projections
Historical Pricing Trends
- Average Wholesale Price (AWP): $X per dose in 2020.
- Recent adjustments: price reductions due to biosimilar competition or market pressures.
- Hospital outpatient drug cost: ranges from $X to $Y per dose.
Factors Influencing Price Trajectory
- Entry of biosimilars or generics reduces incumbent prices.
- Manufacturing cost inflation or deflation.
- Reimbursement rate adjustments.
- Regulatory tariffs or import/export policies.
Short-term (Next 1-2 Years)
Prices are projected to decline by 10-20% as biosimilar competitors gain market share or as manufacturers implement discounts to expand volume. Price stabilization may occur if patent protections or exclusivity periods extend.
Long-term (2-5 Years)
Prices could decrease further by 25-40% if multiple biosimilars penetrate the market extensively. Alternatively, if the drug maintains patent exclusivity or gains new indications, prices may stabilize or increase modestly.
Price Comparison with Similar Drugs
| Drug |
Typical Price Range |
Market Penetration |
Biosimilar Presence |
Price Trend |
| Drug A |
$X-$Y |
High |
None |
Stable or decreasing |
| Drug B |
$Z |
Moderate |
2 biosimilars |
Decreasing trend |
Assumptions Used in Price Projection Models
- Biosimilar market entry at Year 2.
- Steady growth in disease prevalence.
- Stable regulatory and reimbursement environment.
- No major supply chain disruptions.
Key Takeaways
- The current market for the drug indicated by NDC 00904-7302 is characterized by slow growth with increasing competition.
- Prices are likely to decline over the next 2-3 years due to biosimilar entry and competitive pressures.
- Long-term pricing depends on patent protections and expansion into new indications.
- Market share remains limited without increased utilization or market penetration strategies.
FAQs
1. How does biosimilar entry affect prices? Biosimilars typically lower prices by 15-30% upon market entry, accelerating price declines for the original biologic.
2. What factors influence reimbursement for this drug? Reimbursement depends on payer policies, coding, and agreements with hospital or pharmacy networks.
3. Are there upcoming regulatory approvals that could impact this drug's market? Candidate biosimilars or indication expansions can alter competitive dynamics and pricing.
4. How do hospital procurement policies influence pricing? Hospitals often negotiate volume discounts, influencing the actual purchase price versus list or wholesale prices.
5. What are the growth opportunities for this drug? New indications, expanded patient access, or institutional adoption could increase utilization, impacting revenues.
References
- U.S. Food and Drug Administration. (2022). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
- IQVIA. (2022). Prescription Trends and Market Data.
- FDA. (2021). Biosimilar Approval Trends. https://www.fda.gov/drugs/biosimilars
- Pharmaceutical Market Analysis Report 2022.
- CMS. (2022). Reimbursement Policies for Infusion Drugs. https://www.cms.gov
